1,370 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, Holdings Channel reports. The fund bought 1,370 shares of the company’s stock, valued at approximately $29,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC grew its stake in Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after acquiring an additional 3,075,019 shares in the last quarter. State Street Corp boosted its holdings in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Kenvue by 0.9% in the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after purchasing an additional 399,846 shares during the period. Finally, Harris Associates L P raised its position in shares of Kenvue by 7.5% in the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after buying an additional 2,186,114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Finally, Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Stock Down 2.0 %

Shares of NYSE:KVUE opened at $21.29 on Friday. The stock has a market capitalization of $40.82 billion, a P/E ratio of 38.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.46. The stock’s 50-day moving average price is $21.90 and its 200-day moving average price is $21.89. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the company earned $0.31 EPS. Kenvue’s revenue for the quarter was down .4% compared to the same quarter last year. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.85%. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.